Allicense 2010 Breakthrough winner
Sanofi-Aventis / Exelixis
Allicense 2010 Breakthrough Alliance Nominees |
We are pleased to announce the five nominees for the Allicense 2010 Breakthrough Alliance Award! Please vote for the innovative deal you think best addresses the evolving needs of our industry. The nominees are:
|
2010 Nominees
| Companies | Deal |
| Early-Stage Collaboration in Cancer |
| Phase III Collaboration for Cancer Products |
| Phase II Co-Development for Lymphoma Product |
| Phase II Collaboration in Diabetes/Obesity |
| Phase II Collaboration for Depression |
|
The one-page Executive Analyses for each deal is given below. These breakthrough alliance deals were analyzed using best available data from Recap IQ Series by Deloitte. Some of the common elements to the deals include:
• Large upfront cash and/or equity payments
• Shared costs limits
• Clear allocation of decision-making power
• Preservation of commercial rights
Top points of the deals include:
Sanofi-Aventis/Exelixis - Early-Stage Collaboration in Cancer
• $140M upfront for Phase I compounds and backups WW
• Sanofi pays all future R&D costs, financing Exelixis FTE’s
• Lots of milestone payments for future payouts
• Royalty-only structure guarantees steady back-end payments
• Minimum royalty floor ensures revenue for Exelixis
• Decision-making power allocated to avoid disputes | |
Novartis/Incyte - Phase III Collaboration for Cancer Products
• $210M upfront to Incyte for 2 compounds in cancer
• US rights retained by Incyte for one compound
• Novartis pays all R&D costs for its territory
• Incyte pays US costs for one compound
• Royalties on sales of both compounds at back-end
• Incyte not responsible for any launch or commercial costs
• Decision-making allocated to avoid disputes | |
Millennium /Seattle Genetics - Phase II Co-Development for Lymphoma Product
• $60M upfront for ex-US territory
• Seattle Genetics retains rights in US for itself or to be licensed separately
• 50/50 sharing of ex-US R&D costs, excluding Japan costs
• 19 development milestones and 3 sales milestones totaling $230M
• Double-digit royalties on ex-US sales
• Royalty term defined for the length of product sales | |
Takeda /Amylin - Phase II Collaboration in Diabetes/Obesity
• $75M upfront for a Phase II product in diabetes worldwide
• Takeda funds 80% of future U.S. costs and all worldwide costs
• Milestones (~ $100M/product) offsets Amylin costs
• Provision for Takeda loan to cover costs of unanticipated CV study
• Parties pool their research programs with royalties to Amylin on all sales
• Royalty-only structure guarantees steady revenue stream
• Takeda finances Amylin co-promotion | |
AstraZeneca/Targacept - Phase II Collaboration for Depression
• $200M upfront for a Phase II product in depression
• AZ pays 80% of global costs
• AZ pays 100% of costs not supporting a US or EU approval
• Targacept development cost cap – can opt not to fund beyond limit
• 12 development/regulatory milestones up to $540M
• 7 sales milestones up to $500M
• Double-digit royalty structure
• AZ finances Targacept sales force recruitment and detailing for co-promotion | |
|
|
The Allicense 2010 Breakthrough Alliance will be
honored on the evening of May 25, 2010
ALLICENSE 2010 BREAKTHROUGH ALLIANCE AWARDS DINNER
Spend a grand evening amongst other CEOs and Executives at a cocktail reception, dinner and awards ceremony at the Fairmont Hotel. The Allicense 2010 Breakthrough Alliance will be honored on the evening of May 25, 2010. Learn which Biotech and Pharmaceutical Breakthrough Alliance has been selected for top honors by Biotech and Pharma Business Development and Licensing Executives while enjoying cocktails and dinner in these magnificent surroundings.
|
|